论文部分内容阅读
Sildenafil, a selective inhibitor of the cyclic guanosine monophosphate (cGMP) degrading phosphodiestrase 5 (PDE5), induced migraine without aura in 10 of 12 migraine patients and in healthy subjects it induced significantly more headache than placebo. The aim of the present study was to determine whether the pain i nducing effects of sildenafil would be reflected in plasma levels of important s ignalling molecules in migraine: cGMP, cyclic adenosine monophosphate (cAMP) and calcitonin gene related peptide (CGRP). Ten healthy subjects (four women, six men) and 12 patients (12 women) suffering from migraine without aura were includ ed in two separate doubleblind, placebo controlled, cross over studies in whic h placebo or sildenafil 100 mg was administered orally. Plasma levels of CGRP, c AMP and cGMP were determined in blood from the antecubital vein. Despite the abi lity of sildenafil to induce headache and migraine, no significant differences i n plasma levels of CGRP, cGMP and cAMP were detected after sildenafil compared w ith placebo. In conclusion, plasma levels of CGRP, cGMP and cAMP remain normal d uring sildenafil in duced headache or migraine. However, since previous studie s indicate an important role of these signalling molecules, the present study qu estions whether cAMP and cGMP in peripheral.
Sildenafil, a selective inhibitor of the cyclic guanosine monophosphate (cGMP) degrading phosphodiestrase 5 (PDE5), induced migraine without aura in 10 of 12 migraine patients and in healthy subjects it induced significantly more headache than placebo. The aim of the present study was to determine whether the pain i nducing effects of sildenafil would be reflected in plasma levels of important s ignalling molecules in migraine: cGMP, cyclic adenosine monophosphate (cAMP) and calcitonin gene related peptide (CGRP). Ten healthy subjects (four women, six men) and 12 patients (12 women) suffering from migraine without aura were includ ed in two separate doubleblind, placebo controlled, cross over studies in whic h placebo or sildenafil 100 mg was administered orally. Plasma levels of CGRP, c AMP and cGMP were determined in Despite the abi lity of sildenafil to induce headache and migraine, no significant differences in plasma levels of CGRP, cGMP and cAMP were detected after sildenafil compared w ith placebo. In conclusion, plasma levels of CGRP, cGMP and cAMP remain normal d uring sildenafil in duced headache or migraine. However, since ago studie s indicate an important role of these signaling molecules, the present study qu estions whether cAMP and cGMP in peripheral.